Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

Blood cancers such as leukaemia and lymphoma
Inherited genetic disorders including thalassemia and sickle cell disease
Neurological conditions such as cerebral palsy and brain injury
Immune deficiencies and metabolic disorders
Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

Cerebral Palsy
Thalassemia
Leukaemia
HSV Encephalitis
Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

Families gain access to 1,000,000+ stored cord blood units across the network
Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

Order now Find out more

FamiCord Group releases

Patients

7800+

Expand table
No.	Source	Source type	Diagnosis	Medical sector	Year of application	Therapy	Country	Age of the recipient
8501	Cord Blood	Autologous	Cerebral Palsy	Neurology	2011	Experimental Therapy	Portugal	6
8502	Cord Blood	Allogeneic – Related	Chronic Granulomatous Disease	Hematology	2011	Standard Therapy	Poland	7,5
8503	Cord Blood	Allogeneic – Related	Fanconi Anemia	Hematology	2011	Standard Therapy	Poland	12
8504	Cord Blood	Allogeneic – Related	Histiocytosis	Hematology	2011	Standard Therapy	Poland	2,5
8505	Cord Blood	Allogeneic	Scid (Severe Combined Immunodeficiency)	Hematology	2011	Standard Therapy	Germany	1
8506	Cord Blood	Allogeneic – Related	Thalassemia Major	Hematology	2011	Standard Therapy	Turkey	15
8507	Cord Blood	Allogeneic – Related	Thalassemia Major	Hematology	2011	Standard Therapy	Turkey	15
8508	Cord Blood	Autologous	Typ-1-Diabetes	Endocrinology	2011	Experimental Therapy	Germany	2
8509	Bone Marrow Family	Allogeneic	Acute Myeloid Leukemia	Hematology	2011	Standard Therapy	Germany	65
8510	Bone Marrow Family	Allogeneic	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	50
8511	Bone Marrow	Allogeneic	Acute Myeloid Leukemia	Hematology	2011	Standard Therapy	Germany	64
8512	Bone Marrow	Allogeneic	Acute Myeloid Leukemia	Hematology	2011	Standard Therapy	Germany	45
8513	Bone Marrow	Autologous	Coronary Artery Disease	Hematology	2011	Standard Therapy	Germany	68
8514	Bone Marrow	Autologous	Ischemic Cardiomyopathy	Hematology	2011	Standard Therapy	Germany	70
8515	Bone Marrow	Autologous	Ischemic Cardiomyopathy	Hematology	2011	Standard Therapy	Germany	55
8516	Bone Marrow	Autologous	Ischemic Cardiomyopathy	Hematology	2011	Standard Therapy	Germany	64
8517	Bone Marrow	Autologous	Ischemic Cardiomyopathy	Hematology	2011	Standard Therapy	Germany	71
8518	Bone Marrow	Autologous	Ischemic Cardiomyopathy	Hematology	2011	Standard Therapy	Germany	62
8519	Bone Marrow	Autologous	Ischemic Myopathy	Hematology	2011	Standard Therapy	Germany	62
8520	Bone Marrow	Autologous	Ischemic Myopathy	Hematology	2011	Standard Therapy	Germany	69
8521	Bone Marrow	Autologous	Ischemic Myopathy	Hematology	2011	Standard Therapy	Germany	40
8522	Bone Marrow	Autologous	Peripheral Artery Disease	Hematology	2011	Standard Therapy	Germany	74
8523	Bone Marrow	Allogeneic	Severe Aplastic Anemia	Hematology	2011	Standard Therapy	Germany	31
8524	Apheresis	Allogeneic	Acute Lymphoblastic Leukemia	Hematology	2011	Standard Therapy	Germany	41
8525	Apheresis	Allogeneic	Acute Lymphoblastic Leukemia	Hematology	2011	Standard Therapy	Germany	42
8526	Apheresis	Allogeneic	Acute Lymphoblastic Leukemia	Hematology	2011	Standard Therapy	Germany	31
8527	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2011	Standard Therapy	Germany	64
8528	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2011	Standard Therapy	Germany	42
8529	Apheresis	Autologous	Acute Myeloid Leukemia	Hematology	2011	Standard Therapy	Germany	73
8530	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2011	Standard Therapy	Germany	54
8531	Apheresis	Autologous	Acute Myeloid Leukemia	Hematology	2011	Standard Therapy	Germany	70
8532	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2011	Standard Therapy	Germany	65
8533	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2011	Standard Therapy	Germany	69
8534	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2011	Standard Therapy	Germany	25
8535	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2011	Standard Therapy	Germany	48
8536	Apheresis	Allogeneic	Acute Myeloid Leukemia	Hematology	2011	Standard Therapy	Germany	59
8537	Apheresis	Allogeneic	Acute Myeloid Leukemia – Relapse	Hematology	2011	Standard Therapy	Germany	53
8538	Apheresis	Autologous	Anaplastic Lymphoma Kinase Positive Anaplastic Large-Cell Lymphoma	Hematology	2011	Standard Therapy	Germany	60
8539	Apheresis	Autologous	Angioimmunoblastic T-Cell Lymphoma	Hematology	2011	Standard Therapy	Germany	63
8540	Apheresis	Allogeneic	Aplastic Anemia	Hematology	2011	Standard Therapy	Germany	62
8541	Apheresis	Autologous	B-Cell Non-Hodgkin Lymphoma	Hematology	2011	Standard Therapy	Germany	41
8542	Apheresis	Autologous	B-Cell Non-Hodgkin Lymphoma	Hematology	2011	Standard Therapy	Germany	61
8543	Apheresis	Autologous	B-Cell Non-Hodgkin Lymphoma	Hematology	2011	Standard Therapy	Germany	51
8544	Apheresis	Autologous	Central Nervous System Non-Hodgkin Lymphoma	Hematology	2011	Standard Therapy	Germany	41
8545	Apheresis	Allogeneic	Chronic Myelogenous Leukemia	Hematology	2011	Standard Therapy	Germany	62
8546	Apheresis	Autologous	Follicular Lymphoma-Relapse	Hematology	2011	Standard Therapy	Germany	68
8547	Apheresis	Autologous	Germ Cell Tumor	Hematology	2011	Standard Therapy	Germany	28
8548	Apheresis	Autologous	Lymphoblastic Lymphoma	Hematology	2011	Standard Therapy	Germany	49
8549	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2011	Standard Therapy	Germany	62
8550	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2011	Standard Therapy	Germany	51
8551	Apheresis	Autologous	Mantle Cell Lymphoma	Hematology	2011	Standard Therapy	Germany	67
8552	Apheresis	Autologous	Morbus Hodgkin	Hematology	2011	Standard Therapy	Germany	70
8553	Apheresis	Autologous	Morbus Hodgkin	Hematology	2011	Standard Therapy	Germany	24
8554	Apheresis	Autologous	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	58
8555	Apheresis	Autologous	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	70
8556	Apheresis	Autologous	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	59
8557	Apheresis	Autologous	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	44
8558	Apheresis	Autologous	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	52
8559	Apheresis	Autologous	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	70
8560	Apheresis	Autologous	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	55
8561	Apheresis	Autologous	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	69
8562	Apheresis	Autologous	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	58
8563	Apheresis	Autologous	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	58
8564	Apheresis	Autologous	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	60
8565	Apheresis	Autologous	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	56
8566	Apheresis	Autologous	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	66
8567	Apheresis	Autologous	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	57
8568	Apheresis	Autologous	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	47
8569	Apheresis	Allogeneic	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	66
8570	Apheresis	Autologous	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	60
8571	Apheresis	Allogeneic	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	61
8572	Apheresis	Autologous	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	69
8573	Apheresis	Autologous	Multiple Myeloma	Hematology	2011	Standard Therapy	Germany	54
8574	Apheresis	Allogeneic	Myelodysplastic Syndrome	Hematology	2011	Standard Therapy	Germany	68
8575	Apheresis	Allogeneic	Myelofibrosis	Hematology	2011	Standard Therapy	Germany	40
8576	Apheresis	Autologous	Non-Hodgkin Lymphoma	Hematology	2011	Standard Therapy	Germany	47
8577	Apheresis	Autologous	Non-Hodgkin-Lymphoma-Relapse	Hematology	2011	Standard Therapy	Germany	61
8578	Apheresis	Autologous	Non-Hodgkin-Lymphoma-Relapse	Hematology	2011	Standard Therapy	Germany	43
8579	Apheresis	Autologous	Plasmacytoma	Hematology	2011	Standard Therapy	Germany	68
8580	Apheresis	Autologous	Plasmacytoma	Hematology	2011	Standard Therapy	Germany	51
8581	Apheresis	Autologous	Primary Central Nervous System Lymphoma	Hematology	2011	Standard Therapy	Germany	43
8582	Apheresis	Allogeneic	Primary Myelofibrosis	Hematology	2011	Standard Therapy	Germany	36
8583	Apheresis	Allogeneic	Refractory Acute Myeloid Leukemia	Hematology	2011	Standard Therapy	Germany	27
8584	Apheresis	Autologous	Richter's Transformation	Hematology	2011	Standard Therapy	Germany	71
8585	Apheresis	Allogeneic	T-Cell Non-Hodgkin Lymphoma	Hematology	2011	Standard Therapy	Germany	50
8586	Apheresis	Allogeneic	T-Cell Non-Hodgkin Lymphoma	Hematology	2011	Standard Therapy	Germany	48
8587	Apheresis	Allogeneic	T-Cell Non-Hodgkin Lymphoma Relapse	Hematology	2011	Standard Therapy	Germany	56
8588	Apheresis	Autologous	Testicular Cancer Relapse	Hematology	2011	Standard Therapy	Germany	43
8589	Cord Blood	Autologous	Brain Damage	Neurology	2010	Experimental Therapy	Germany	5
8590	Cord Blood	Autologous	Brain Damage	Neurology	2010	Experimental Therapy	Germany	4
8591	Cord Blood	Autologous	Cerebral Palsy	Neurology	2010	Experimental Therapy	Portugal	1
8592	Cord Blood	Autologous	Cerebral Palsy	Neurology	2010	Experimental Therapy	Portugal	1
8593	Cord Blood	Autologous	Cerebral Palsy	Neurology	2010	Experimental Therapy	Portugal	6
8594	Cord Blood	Autologous	Cerebral Palsy	Neurology	2010	Experimental Therapy	UK	3
8595	Cord Blood	Allogeneic – Related	Pre-B Acute Lymphoblastic Leukemia	Hematology	2010	Standard Therapy	Hungary	1,5
8596	Cord Blood	Autologous	Typ-1-Diabetes	Endocrinology	2010	Experimental Therapy	Germany	3
8597	Cord Blood	Autologous	Typ-1-Diabetes	Endocrinology	2010	Experimental Therapy	Germany	2
8598	Bone Marrow	Allogeneic	Acute Myeloid Leukemia	Hematology	2010	Standard Therapy	Germany	57
8599	Bone Marrow	Autologous	Chronic Ischemic Cardiomyopathy	Hematology	2010	Standard Therapy	Germany	71
8600	Bone Marrow	Autologous	Coronary Artery Disease	Hematology	2010	Standard Therapy	Germany	75

Page 86 of 89 1 84 85 86 87 88 89

Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

100% infusion success rate

For samples released for transplant.

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

Expand table
Sample release date	Medical condition	Recipient relationship	Age of the recipient	Unit volume	Medical center	Country
2005.11	Thalassemia	Allogeneic (Sibling)	4 Years	144ml	Mount Vernon Hospital	Singapore
2005.11	Leukaemia	Allogeneic (Sibling)	Restricted	Restricted	Stem Cells and Immunology Department, Birmingham	UK
2007.02	Thalassemia	Allogeneic (Sibling)	7 Years	76ml	Kinderlink der Tu Munchen	Germany
2009.08	Cerebral Palsy	Autologous (Self)	3 Years	51ml	Duke University, North Carolina	USA
2010.01	Cerebral Palsy	Autologous (Self)	3 Years	81ml	Duke University, North Carolina	USA
2013.10	Thalassemia	Allogeneic (Sibling)	5 Years	58ml	Catherine Lewis Centre, Hammersmith	UK
2014.01	Leukaemia	Allogeneic (Sibling)	4 Years	71ml	Medizinische Hochschule, Hanover	Germany
2014.05	Cerebral Palsy	Autologous (Self)	1 year	68ml	Duke University, North Carolina	USA
2014.06	HSV Encephalitis & NMDA Receptor Antibody Virus	Autologous (Self)	2 Years	57ml	Duke University, North Carolina	USA
2014.08	Hypoxic Ischemic Encephalopathy (HIE)	Autologous (Self)	3 Months	39ml	Duke University, North Carolina	USA
2015.02	Hypoxic Ischemic Encephalopathy (HIE)	Autologous (Self)	6 Months	53ml	Duke University, North Carolina	USA
2015.03	Severe Combined Immune Deficiency	Autologous (Self)	3 Months	74ml	Duke University, North Carolina	USA
2015.03	Sickle Cell Disease	Allogeneic (Sibling)	2 .5 Years	57ml	BLK Hospital, New Delhi	India
2015.11	Thalassemia	Allogeneic (Sibling)	12 Years	87ml	Children’s Hospital of Pittsburgh of UPMC	USA
2016.03	Cerebral Palsy	Allogeneic (Sibling)	6 Years	101ml	Duke University, North Carolina	USA
2017.04	Lymphoblastic Leukaemia (^1)	N/A (Identical twin girls)	Restricted	125ml	Bambin Gesu Childrens’ Hospital, Rome	Italy
2017.06	Cerebral Palsy	Autologous (Self)	7 Years	82ml	Duke University, North Carolina	USA
2017.06	Cerebral Palsy	Autologous (Self)	3.4 Years	132ml	Duke University, North Carolina	USA
2018.03	Autism	Autologous (Self)	5.4 Years	73ml	Duke University, North Carolina	USA
2018.03	Cerebral Palsy	Autologous (Self)	3.4 years	132ml	Duke University, North Carolina	USA
2019.06	Cerebral Palsy	Allogeneic (Sibling)	3 Years	104ml	Duke University, North Carolina	USA
2022.02	Cerebral Palsy	Allogeneic (Sibling)	11 Years	185ml	Duke University, North Carolina	USA
2023.08	Cerebral Palsy	Allogeneic (Sibling)	3 Years	46ml	Duke University, North Carolina	USA
2024.01	Thalassaemia	Allogeneic (Sibling)	8 Years	45ml	Cincinnati Children’s Hospital Medical Center	USA